Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for: a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, orb) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); orc) evaluation of response to PRRT therapy; ord) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN. (R) (Anaes.)
Whole body 68Ga-DOTA-somatostatin receptor agonist PET study for: a) staging of histologically confirmed neuroendocrine neoplasm (NEN) considered surgically incurable on conventional imaging, orb) evaluation of somatostatin receptor expression of histologically confirmed and inoperable NEN, either locally advanced or metastatic, under consideration for peptide receptor radionuclide therapy (PRRT); orc) evaluation of response to PRRT therapy; ord) evaluation of suspected recurrent or metastatic disease in known somatostatin receptor positive NEN. (R) (Anaes.)
| Release | Change | Old | New |
|---|---|---|---|
| November 2025 | Listed | — | $953.0 |
Data sourced from Australian Government publications · Not an official government service